|
WO2021045184A1
|
|
Therapeutic agent for polycythemia
|
|
WO2020105621A1
|
|
Inhibitor of cellular iron uptake
|
|
WO2017061602A1
|
|
Antibody capable of specifically binding to cd147 molecule, and use thereof
|
|
AU2014201659A1
|
|
Anti-cadherin antibody
|
|
SG11201506358PA
|
|
Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
|
|
WO2014065402A1
|
|
Anti-human cd40 monoclonal antibody, and use thereof
|
|
JP2016011258A
|
|
Anti human cd40 monoclonal antibody and use thereof
|
|
WO2012176765A1
|
|
Anti-human p-cadherin (cdh3) recombinant antibody
|
|
WO2012153707A1
|
|
Antibody specifically recognising transferrin receptor
|
|
KR20150003251A
|
|
Conjugate Of Anti-CDH3(P-Cadherin) Antibody And Drug
|
|
RS57646B1
|
|
Anti-cdh3 antibody having high internalization capacity
|
|
JP2012053034A
|
|
Inflammatory state detection method
|
|
JP2011239784A
|
|
Acquisition of antibody against cell surface antigen, and antigen identification of the same
|
|
JP2014015396A
|
|
High-affinity anti-cdh3 antibody
|
|
JP2011001267A
|
|
Therapeutic agent for colon cancer
|
|
JP2010280568A
|
|
Diagnostic agent and therapeutic agent for lung cancer, prostate cancer, breast cancer, ovarian cancer and melanoma
|
|
JP2009014521A
|
|
Diagnosis method of sleep apnea syndrome
|
|
JP2010133705A
|
|
Diagnostic drug and curative medicine of cancer
|
|
JP2008209369A
|
|
Diagnostic drug and curative drug for renal cancer
|
|
JP2007192557A
|
|
Method for monitoring hepatic disease of c-type hepatitis case becoming serious, and hepatic cancer diagnosis method
|
